Loading stock…

Prestige Consumer Healthcare Inc. (PBH) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Prestige Consumer Healthcare Inc.

PBHMarket cap $2.25BPrice $47.6

Country🇺🇸United States

SectorHealthcare

IndustryPharmaceuticals

Sells household names like Monistat, Summer's Eve, and Clear Eyes through drugstores and supermarkets. Skips the risky drug-discovery game entirely, instead buying up beloved over-the-counter brands and squeezing steady cash flow out of shelf space nobody else wants.

In Bastion Portfolios?

52W Return-23%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)-1%2

Revenue Forecast

Rev CAGR (1y)+19%8

Rev CAGR (3y)+9%6

Rev CAGR (5y)+4%3

Earnings Forecast

EPS Growth Y+1+17%8

EPS Growth Y+2+12%7

EPS Growth Y+3+0%4

Quality

Margins

EBIT Margin27%8

Net Income Margin16%7

Free Cash Flow Margin21%8

Debt

Net Debt/EBITDA5.61

Efficiency

ROE9%4

ROA4%6

Earnings Stability66

GEAR+STRONG71

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)108

P/E Ratio (Forward 3y)98

P/BV1.29

EV Multiples

EV/EBITDA Fwd106

EV/EBIT Fwd118

Yield

Free Cash Flow Yield10.4%9

Dividend Yieldna–

Momentum

Short term

1 month return-4%5

3 month return-1%6

YTD return-23%2

Mid term

Price vs 52wHigh67%3

1 year return-25%2

Long term

3 year return-19%2

5 year return-18%3

Risk Shield

Price Risk

Beta0.48

Volatility33%6

Free Cash Flow

Free Cash Flow Margin21%8

Free Cash Flow Yield10.4%9

Quality

ROCE8%4

Earnings Stability66

Net Debt/EBITDA5.61

02Growth

Is it actually growing, and how fast?

PBHPrestige Consumer Healthcare

Revenue FY26$1.1B

GROWTH RATING↗

AVERAGE46 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-1%2

Revenue, next 1Y+19%8

Revenue, next 3Y, CAGR+9%6

Revenue, next 5Y, CAGR+4%3

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+17%8

EPS growth, FY28E+12%7

EPS growth, FY29E+0%4

GROWTH ASSESSMENT

STRENGTHS

After shrinking over the last 3 years, revenue is set to grow 9%/yr from here.

Earnings are set to grow in step with sales (EPS about 12%/yr vs revenue 9%/yr).

WATCH

A mid-pack grower, ahead of 46% of companies worldwide.

Revenue is set to grow 9%/yr over the next 3 years, a little ahead of the market.6/10

WEAKNESSES

Revenue fell 1%/yr over the last 3 years, behind 80% of companies worldwide.2/10

Over five years revenue is set to grow 4%/yr, behind 70% of companies worldwide.3/10

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK19 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%5

3-month return-1%6

YTD return-23%2

MID & LONG-TERM▾SCORE

% of 52-week high67%3

1-year return-25%2

3-year return-19%2

5-year return-18%3

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Returns sit at the market level over the past month (-4%) and over three months (-1%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-19% over three years and -18% over five), behind 70% of the market.

It's down 25% over the past year, now 33% below its 52-week high. That is lagging the market.

The stock is underperforming so far this year (-23%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Prestige Consumer Healthcare Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

PBHPrestige Consumer Healthcare

Revenue FY26$1.1B

GROWTH RATING↗

AVERAGE46 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-1%2

Revenue, next 1Y+19%8

Revenue, next 3Y, CAGR+9%6

Revenue, next 5Y, CAGR+4%3

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+17%8

EPS growth, FY28E+12%7

EPS growth, FY29E+0%4

GROWTH ASSESSMENT

STRENGTHS

After shrinking over the last 3 years, revenue is set to grow 9%/yr from here.

Earnings are set to grow in step with sales (EPS about 12%/yr vs revenue 9%/yr).

WATCH

A mid-pack grower, ahead of 46% of companies worldwide.

Revenue is set to grow 9%/yr over the next 3 years, a little ahead of the market.6/10

WEAKNESSES

Revenue fell 1%/yr over the last 3 years, behind 80% of companies worldwide.2/10

Over five years revenue is set to grow 4%/yr, behind 70% of companies worldwide.3/10

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK19 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%5

3-month return-1%6

YTD return-23%2

MID & LONG-TERM▾SCORE

% of 52-week high67%3

1-year return-25%2

3-year return-19%2

5-year return-18%3

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Returns sit at the market level over the past month (-4%) and over three months (-1%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-19% over three years and -18% over five), behind 70% of the market.

It's down 25% over the past year, now 33% below its 52-week high. That is lagging the market.

The stock is underperforming so far this year (-23%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Prestige Consumer Healthcare Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community